Identification of patients with Pseudomonas aeruginosa respiratory tract infections at greatest risk of infection with -carbapenemresistant isolates

Infection Control and Hospital Epidemiology

Volumn 28, Issue 8, 2007, Pages 959-965

  Lodise Jr , Thomas P ^a,b   Miller, Chris ^a,c   Patel, Nimish ^a   Graves, Jeffrey ^a   McNutt, Louise Anne ^d  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b ORDWAY RESEARCH INSTITUTE   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AZTREONAM; CARBAPENEM; CEFEPIME; CIPROFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; ARTIFICIAL VENTILATION; BACTERIUM ISOLATE; DEMOGRAPHY; DRUG EXPOSURE; EMPIRIC ANTIBIOTIC THERAPY; FEMALE; GRAM NEGATIVE INFECTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; NONHUMAN; PROBABILITY; PSEUDOMONAS AERUGINOSA; REGRESSION ANALYSIS; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK FACTOR; TERTIARY HEALTH CARE; TREATMENT PLANNING; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; RESPIRATION, ARTIFICIAL; RESPIRATORY TRACT INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 34547686248     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/518972     Document Type: Article

References (33)

1. Kang CI, Kim SH, Kim HB, et al. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome. Clin Infect Dis 2003; 37:745-751.
2. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49:760-766.
3. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-474.
4. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244:379-386.
5. Lodise TP, McKinnon PS, Swiderski L, Rybak MJ. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. Clin Infect Dis 2003; 36:1418-1423.
6. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306-1311.
7. Kollef MH. Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of the carbapenems. Respir Care 2004; 49:1530-1541.
8. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002; 34:634-640.
9. Tacconelli E, Tumbarello M, Bertagnolio S, et al. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: analysis of trends in prevalence and epidemiology. Emerg Infect Dis 2002; 8:220-221.
10. Obritsch MD, Fish DN, MacLaren R, et al. National surveillance of antimicrobial resistance in Pseudomonas aeruginosa isolates obtained from intensive care unit patients from 1993 to 2002. Antimicrob Agents Chemother 2004; 48:4606-4610.
11. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-485.
12. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes IM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128-140.
13. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-829.
14. Criteria Commitee, New York Heart Association. Diagnosis of the Heart and Blood Vessels: Nonmenclature and Criteria for Diagnosis. 7th ed. Boston: Little, Brown; 1973.
15. Clinical Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard - Ninth Edition. Wayne, PA: CLSI; 2006:M02-M9.
16. Zhang H, Burthon S. Recursive partitioning in the health sciences. In: Dietz K, Gail M, Krickeberg K, Singer B, eds. Recursive Partitioning in the Health Sciences. New York: Springer; 1999:226.
17. McNutt LA, Wu C, Xue X, Hafner JP. Estimating the relative risk in cohort studies and clinical trials of common outcomes. Am J Epidemiol 2003; 157:940-943.
18. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol 2005; 162:199-200.
19. Lodise TP Jr, McKinnon PS, Rybak M. Prediction model to identify patients with Staphylococcus aureus bacteremia at risk for methicillin resistance. Infect Control Hosp Epidemiol 2003; 24:655-661.
20. Harris AD, Smith D, Johnson JA, Bradham DD, Roghmann MC. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 2002; 34:340-345.
21. Zavascki AP, Cruz RP, Goldani LZ. Risk factors for imipenem-resistant Pseudomonas aeruginosa: a comparative analysis of two case-control studies in hospitalized patients. J Hosp Infect 2005; 59:96-101.
22. Ozkurt Z, Ertek M, Erol S, Altoparlak U, Akcay MN. The risk factors for acquisition of imipenem-resistant Pseudomonas aeruginosa in the burn unit. Burns 2005; 31:870-873.
23. Troillet N, Samore MH, Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 1997; 25:1094-1098.
24. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO. Imipenem resistance among Pseudomonas aeruginosa isolates: risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006; 27:893-900.
25. Piddock LJ. Mechanisms of resistance to fluoroquinolones: state-of-the-art 1992-1994. Drugs 1995; 49(suppl 2):29-35.
26. Suvarna SK, al-Wali WI, Locke TJ. Morphological changes in Pseudomonas aeruginosa secondary to ciprofloxacin. Histopathology 1997; 31:482-483.
27. Pai H, Kim J, Kim J, Lee JH, Choe KW, Gotoh N. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 2001; 45:480-484.
28. Aubert G, Pozzetto B, Dorche G. Emergence of quinolone-imipenem cross-resistance in Pseudomonas aeruginosa after fluoroquinolone therapy. J Antimicrob Chemother 1992; 29:307-312.
29. Epp SF, Kohler T, Plesiat P, Michea-Hamzehpour M, Frey J, Pechere JC. C-terminal region of Pseudomonas aeruginosa outer membrane porin OprD modulates susceptibility to meropenem. Antimicrob Agents Chemother 2001; 45:1780-1787.
30. Kohler T, Epp SF, Curty LK, Pechere JC. Characterization of MexT, the regulator of the MexE-MexF-OprN multidrug efflux system of Pseudomonas aeruginosa. J Bacteriol 1999; 181:6300-6305.
31. Kohler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob Agents Chemother 1999; 43:424-427.
32. Harris AD, Carmeli Y, Samore MH, Kaye KS, Perencevich E. Impact of severity of illness bias and control group misclassification bias in case-control studies of antimicrobial-resistant organisms. Infect Control Hosp Epidemiol 2005; 26:342-345.
33. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y. Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, enterococci, and Escherichia coli. Clin Infect Dis 2002; 34:1558-1563.